ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g [h] i j k l m n o p q r s t u v w x y z
  • Abstract Number: 2093
    Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort
  • Abstract Number: 1381
    Health Related Quality of Life in Children with Systemic Lupus Erythematosus
  • Abstract Number: 0058
    Health System Improvement in Inpatient ANA and Serologic Test Utilization
  • Abstract Number: 2070
    Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis
  • Abstract Number: 1798
    Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
  • Abstract Number: 0059
    Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
  • Abstract Number: 2006
    Healthcare Resource Utilization and Economic Burden of Patients with Adequate and Inadequate Responses to Advanced Therapies for Rheumatoid Arthritis in Japan
  • Abstract Number: 1818
    Hepatic Steatosis and Fibrosis in Patients with Gout Detected by Elastography
  • Abstract Number: 1864
    Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response
  • Abstract Number: 1403
    Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
  • Abstract Number: 0555
    Heterogeneity in Origin and Function of Distinct Human Synovial-tissue Dendritic Cells in Health, Active Rheumatoid Arthritis (RA) and RA in Disease Remission
  • Abstract Number: 0769
    Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
  • Abstract Number: 2123
    Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis
  • Abstract Number: 0257
    High Density Lipoprotein Bound miR-1246 Is Enriched in Patients with Rheumatoid Arthritis and Is Proinflammatory
  • Abstract Number: 1801
    High Frequency of Structural Damage in the Lower Spine of Patients with Chondrocalcinosis
  • Abstract Number: 1109
    High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease
  • Abstract Number: 0964
    High Rates of Fetal Growth Restriction in Systemic Lupus Erythematosus Pregnancies
  • Abstract Number: 0807
    High Throughput Analyses for the Study of Synovial Tissue Biopsy from Inflammatory Arthritis Patients
  • Abstract Number: 1490
    High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis
  • Abstract Number: 1701
    High TNFAIP3-Transfected Cell Activity: An In Vitro Model for Phagocyte Study of Monogenic Behçet’s Disease Pathophysiology
  • Abstract Number: 0563
    High-Dimensional Immunophenotyping with Mass Cytometry Reveals Unique Immune Cell Aberrations in Patients with Undiagnosed Inflammatory and Autoimmune Diseases
  • Abstract Number: 0310
    Higher Baseline Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Predict Therapeutic Efficacy of Abatacept in Moderate to Severe Rheumatoid Arthritis
  • Abstract Number: 0449
    Higher Disease Acuity at Presentation and Increased Lower Respiratory Involvement in Hispanic and Black Patients with ANCA-Associated Vasculitis
  • Abstract Number: 2252
    Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis
  • Abstract Number: 1181
    Hippo Pathway Effectors Promote and Maintain Myofibroblast Differentiation and Endothelial-to-mesenchymal Transition in Systemic Sclerosis
  • Abstract Number: 1885
    Histopathological Patterns of Muscle Involvement and Clinical Correlations in a Retrospective Cohort of Scleroderma Patients
  • Abstract Number: 1299
    Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children
  • Abstract Number: 0774
    HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
  • Abstract Number: 0743
    Home-Based Telehealth in Rheumatology: A Systematic Review & Narrative Synthesis
  • Abstract Number: 1871
    Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
  • Abstract Number: PP10
    How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology
  • Abstract Number: PP13
    How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health
  • Abstract Number: 1368
    How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey
  • Abstract Number: 2198
    How Did a Mandatory Switching Policy for Biosimilars in Canada Impact Uptake and Spending?
  • Abstract Number: 1516
    How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis
  • Abstract Number: 1495
    How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
  • Abstract Number: 0395
    How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
  • Abstract Number: 1028
    How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?
  • Abstract Number: 1497
    How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
  • Abstract Number: 1288
    How Often Do We Provide Relevant and Patient Centric Discharge Instructions in Rheumatology? A Single Academic Center Clinic Experience
  • Abstract Number: 2141
    How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
  • Abstract Number: 0666
    HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE
  • Abstract Number: 0786
    Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis
  • Abstract Number: 0753
    Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study
  • Abstract Number: 0785
    Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study
  • Abstract Number: 1604
    Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial
  • Abstract Number: 1654
    Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares
  • Abstract Number: 0983
    Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
  • Abstract Number: 0815
    Hyper-IgG4 in Patients with Systemic Autoinflammatory Disease
Jump to:  View All • a b c d e f g [h] i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology